Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 352-367
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.352
Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
Wen-Guang Pei, Wen-Zheng Chen, Yu-Kang Wu, Sheng-Xing Tan, Zhi-Gang Jie
Wen-Guang Pei, Wen-Zheng Chen, Yu-Kang Wu, Sheng-Xing Tan, Zhi-Gang Jie, Department of Gastrointestinal Surgery, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Author contributions: Pei WG, Jie ZG, Chen WZ, Tan SX, Wu YK contributed to the conception and design; Pei WG, Jie ZG, Chen WZ, Tan SX, Wu YK contributed to the data collection and extraction, statistical data analysis and software utilization; Pei WG, Chen WZ, Wu YK was involved in methodology, data curation and formal analysis; Pei WG, Jie ZG contributed to the manuscript drafting; Pei WG, Jie ZG, Chen WZ, Tan SX, Wu YK contributed to the manuscript revision, and approval of the final manuscript.
Supported by The National Natural Science Foundation of China, No. 81960503.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Gang Jie, MMed, Chief Doctor, Professor, Department of Gastrointestinal Surgery, First Affiliated Hospital of Nanchang University, No. 17 Yongwai Main Street, Donghu District, Nanchang 330006, Jiangxi Province, China. jiezg123@126.com
Received: October 10, 2022
Peer-review started: October 10, 2022
First decision: October 20, 2022
Revised: October 23, 2022
Accepted: November 28, 2022
Article in press: November 28, 2022
Published online: February 15, 2023
Core Tip

Core Tip: This systematic review shows that there is an increasing number of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors that are being reported in patients with gastric cancer or gastroesophageal junction cancer. This is particularly severe organ-specific irAEs and death because of irAEs, which poses significant challenges for clinical oncologists. Therefore, to help clinicians effectively identify and manage irAEs as well as strike a balance, a comprehensive understanding, systematic prediction, and appropriate management of the adverse events are critical.